Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Trial Details
- NCT ID
- NCT03696680
- Phase
- PHASE2
- Sponsor
- Centre Francois Baclesse
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- FSRT Stereotactic radiation therapy
- Locations (sample)
- Avranches, France|48.68436,-1.35686
- Caen, France|49.18585,-0.35912
- Lyon, France|45.74906,4.84789
- Nancy, France|48.68439,6.18496
Key Eligibility Criteria
- Age\> 18 years
- Performance Status 0 or 1
- Patient with less than 4 brain metastases \[of a solid tumor, including melanoma, with a histologically proven diagnosis for the solid tumor; Patie…
- Brain injury (s) measuring between 5 and 30 mm in diameter
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →